(Total Views: 728)
Posted On: 03/17/2021 9:30:31 PM
Post# of 72440
Thanks for the correction .I inadvertently expanded the trial to 200 patients.
I share your enthusiasm about the Brilacidin for Covid-19 clinical trial. Hopefully the unique combination of being virucidal, anti-inflammatory as well as a broad spectrum antibiotic will prove efficacious in these sick patients.
It is possible the first 3 days will eliminate the virus while days 4 and 5 will prevent the immunologic over reaction which causes so many of the complications of Covid 19. Regardless of whether Brilacidin is given 3 or 5 days, it's long half life will extend its pharmacologic benefit.
We already know the current standard of care is inadequate for Covid19, I am expecting the robust preclinical in vitro RBL results will extend to the clinical trial. We will know for sure soon.
GLTA,Farrell
I share your enthusiasm about the Brilacidin for Covid-19 clinical trial. Hopefully the unique combination of being virucidal, anti-inflammatory as well as a broad spectrum antibiotic will prove efficacious in these sick patients.
It is possible the first 3 days will eliminate the virus while days 4 and 5 will prevent the immunologic over reaction which causes so many of the complications of Covid 19. Regardless of whether Brilacidin is given 3 or 5 days, it's long half life will extend its pharmacologic benefit.
We already know the current standard of care is inadequate for Covid19, I am expecting the robust preclinical in vitro RBL results will extend to the clinical trial. We will know for sure soon.
GLTA,Farrell
(10)
(0)Scroll down for more posts ▼
